Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07761520

Prevention of Ischemia in Aneurysmal Subarachnoid Hemorrhage Through Remote Ischemic Preconditioning

Aneurysmal subarachnoid hemorrhage (SAH) is a severe form of stroke caused by bleeding around the brain. Despite early treatment of the initial hemorrhage, many patients develop delayed cerebral ischemia several days later, which is a major cause of neurological disability, cognitive impairment, and mortality. Current preventive and therapeutic strategies are only partially effective, highlighting the need for new treatment approaches.

This study investigates a simple, non-invasive technique called remote ischemic preconditioning (RIPC). RIPC consists of brief, repeated cycles of limb ischemia and reperfusion induced by a blood pressure cuff. RIPC is thought to activate endogenous protective mechanisms that may improve the brain's tolerance to ischemia. Although beneficial effects have been reported in experimental models and cardiovascular diseases, its clinical efficacy in aneurysmal SAH remains uncertain.

In this randomized, controlled, single-blinded, multicenter study, adult patients admitted with aneyrysmal SAH will be randomly assigned to receive RIPC or a sham procedure. The RIPC group will undergo cycles of brief lower-limb ischemia using a pressure cuff, while the sham group will receive an identical procedure without inducing ischemia. Patients and neurologists assessing outcomes will remain blinded to group allocation.

The intervention will be performed every two days from day 2 to day 10 after hemorrhage. Neurological outcome will be assessed at 3 months using the modified Rankin Scale. Secondary outcomes include mortality at 3 months, long-term neurological and cognitive function outcomes at 12 months, and the incidence of adverse events related to the procedure.

If effective, RIPC could become a simple, low-cost, widely accessible method to reduce disability after SAH. The results may help improve future treatment strategies for this severe condition.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age over 18 years
  • Hospitalization for aneurysmal subarachnoid hemorrhage confirmed by CT scan and/or lumbar puncture
  • Confirmation of intracranial aneurysm by CT angiography and/or cerebral angiography
  • Written informed consent obtained from the patient or legal representative
  • Affiliation to a social security system

Exclusion criteria

  • Skin, orthopedic, or vascular conditions of the limbs contraindicating ischemic preconditioning (e.g., ulcers, fractures, deep vein thrombosis)
  • Pregnancy
  • Withdrawal of informed consent

Treatment and study plan

Remote ischemic preconditioning

Procedure

Three cycles of lower-limb ischemia and reperfusion using a blood pressure cuff inflated to 20 mmHg above systolic blood pressure for 5 minutes followed by 5 minutes of reperfusion. The procedure is performed every two days from day 2 to day 10 after aneurysmal subarachnoid hemorrhage.

Sham ischemic preconditioning

Procedure

Identical procedure to the experimental arm, except the cuff is inflated to only 30 mmHg, insufficient to induce ischemia, giving the sensation of pressure without therapeutic effect. Performed every two days from day 2 to day 10 post-hemorrhage.

Primary outcomes

  1. Neurological Functional Outcome at 3 Months (mRS)

    Time frame: 3 months (+/- 15 days) post-aneurysmal subarachnoid hemorrhage

    Assessment of neurological disability and dependency using the modified Rankin Scale (mRS) performed by a blinded neurologist. The mRS is a 6-point scale (0 to 5), with 5 being a severe disability.

Secondary outcomes

  1. Evaluation of mortality at 3 Months

    Time frame: From day 0 to 3 months post-hemorrhage

    Comparison of all-cause mortality between the RIPC group and the sham group

  2. Long-term Neurological Outcome at 12 Months (mRS)

    Time frame: 12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage

    Assessment of long-term neurological disability and dependency using the modified Rankin Scale (mRS) performed by a blinded neurologist. The mRS is a 6-point scale (0 to 5), with 5 being a severe disability.

  3. Evaluation of Cognitive Function at 12 months (MMSE)

    Time frame: 12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage

    Evaluation of cognitive performance assessed using the Mini-Mental State Examination (MMSE). The MMSE score ranks from 0 to 30, with 30 being a normal congnitive performance and 0 serious cognitive impairments.

  4. Evaluation of Cognitive Function at 12 months (MoCA)

    Time frame: 12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage

    Evaluation of cognitive performance assessed using the Montreal Cognitive Assessment (MoCA). The MoCA is scored out of 30 points, with high scores suggesting mild or no cognitive impairments, and low scores severe cognitive impairments.

  5. Safety Outcomes

    Time frame: From day 0 until 12 months post-aneurysmal subarachnoid hemorrhage.

    Incidence, nature, and severity of adverse events and serious adverse events occurring during the study period.

Study contacts

Contact information is provided by the study sponsor or research team.

Eve Ledoux

CONTACT

[email protected]

+33 4 92 03 27 29

Jacques Sedat, MD

CONTACT

[email protected]

+33 4 92 03 38 07

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Remote Ischemic Preconditioning (RIPC) and Aneurysmal Subarachnoid Hemorrhage (SAH)

Acronym: HMA

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Aug 12, 2026
Registry last updated
Aug 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.